Xu Wang1, Xiao-Bo Guo2, Xiao-Chun Shen3, Hao Zhou1, Dan-Wei Wan4, Xiao-Feng Xue1, Ye Han1, Bin Yuan1, Jin Zhou1, Hong Zhao1, Qiao-Ming Zhi1, Yu-Ting Kuang1. 1. Department of General Surgery, The First Affiliated Hospital of Soochow University Suzhou 215006, China. 2. Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250021, China. 3. Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University Suzhou 215006, China. 4. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-Sen University Guangzhou 510006, China.
Abstract
OBJECTIVE: In published studies, Y-box binding protein-1 (YB-1) correlated with the prognosis of patients with breast cancer (BC), but the specific role of YB-1 is still unclear. Our study aimed to evaluate the prognostic value of YB-1 in BC patients using meta-analysis based on the published studies. METHODS: We searched the relevant literatures deadline for June 2014 in databases, including PubMed, Embase, Medline and Cochrane library, and finally 8 studies were included in our study. Our study contained 1094 BC patients with 398 YB-1 positive and 696 YB-1 negative. RESULTS: Our results showed that YB-1 abnormal expression did not correlated with the lymph node status [OR = 1.258, 95% CI = 0.895-1.769, P = 0.186], high histological grade [OR = 2.709, 95% CI = 0.861-8.530, P = 0.089], histological type [OR = 0.837, 95% CI = 0.526-1.331, P = 0.452], P53 status [OR = 2.006, 95% CI 0.686-5.865, P = 0.203] and PR [OR = 0.607, 95% CI = 0.347-1.061, P = 0.080] in BC patients. But YB-1 over-expression was associated with other unfavorable factors: ER negativity [OR = 0.604, 95% CI = 0.388-0.941, P = 0.026], HER2 positivity [OR = 3.841, 95% CI = 2.637-5.594, P = 0.000], and high tumorous T stage [OR = 2.169, 95% CI = 1.295-3.632, P = 0.003]. In addition, our data suggested that high YB-1 expression had an adverse impact on 5-year OS [RR = 2.767, 95% CI = 2.054-3.727, P = 0.000] in BC patients. CONCLUSIONS: Our findings implied that YB-1 might a novel biomarker to predict the prognosis of BC, and could be a potential direction for developing diagnostic and therapeutic approaches in BC.
OBJECTIVE: In published studies, Y-box binding protein-1 (YB-1) correlated with the prognosis of patients with breast cancer (BC), but the specific role of YB-1 is still unclear. Our study aimed to evaluate the prognostic value of YB-1 in BC patients using meta-analysis based on the published studies. METHODS: We searched the relevant literatures deadline for June 2014 in databases, including PubMed, Embase, Medline and Cochrane library, and finally 8 studies were included in our study. Our study contained 1094 BC patients with 398 YB-1 positive and 696 YB-1 negative. RESULTS: Our results showed that YB-1 abnormal expression did not correlated with the lymph node status [OR = 1.258, 95% CI = 0.895-1.769, P = 0.186], high histological grade [OR = 2.709, 95% CI = 0.861-8.530, P = 0.089], histological type [OR = 0.837, 95% CI = 0.526-1.331, P = 0.452], P53 status [OR = 2.006, 95% CI 0.686-5.865, P = 0.203] and PR [OR = 0.607, 95% CI = 0.347-1.061, P = 0.080] in BC patients. But YB-1 over-expression was associated with other unfavorable factors: ER negativity [OR = 0.604, 95% CI = 0.388-0.941, P = 0.026], HER2 positivity [OR = 3.841, 95% CI = 2.637-5.594, P = 0.000], and high tumorous T stage [OR = 2.169, 95% CI = 1.295-3.632, P = 0.003]. In addition, our data suggested that high YB-1 expression had an adverse impact on 5-year OS [RR = 2.767, 95% CI = 2.054-3.727, P = 0.000] in BC patients. CONCLUSIONS: Our findings implied that YB-1 might a novel biomarker to predict the prognosis of BC, and could be a potential direction for developing diagnostic and therapeutic approaches in BC.
Entities:
Keywords:
YB-1; breast cancer; meta-analysis; prognosis
Authors: David H Lovett; Sunfa Cheng; Leslie Cape; Allan S Pollock; Peter R Mertens Journal: Biochem Biophys Res Commun Date: 2010-07-01 Impact factor: 3.575
Authors: Karen To; Abbas Fotovati; Kristen M Reipas; Jennifer H Law; Kaiji Hu; Jing Wang; Arezoo Astanehe; Alastair H Davies; Lawrence Lee; Anna L Stratford; Afshin Raouf; Pauline Johnson; Isabelle M Berquin; Hans-Dieter Royer; Connie J Eaves; Sandra E Dunn Journal: Cancer Res Date: 2010-03-23 Impact factor: 12.701
Authors: E Mylona; S Melissaris; I Giannopoulou; I Theohari; C Papadimitriou; A Keramopoulos; L Nakopoulou Journal: Eur J Surg Oncol Date: 2013-09-15 Impact factor: 4.424
Authors: Adam Maciejczyk; Jolanta Szelachowska; Marcin Ekiert; Rafał Matkowski; Agnieszka Hałoń; Hermann Lage; Paweł Surowiak Journal: Anticancer Res Date: 2012-08 Impact factor: 2.480
Authors: Alexander Kaszubiak; Annette Kupstat; Ursula Müller; Romy Hausmann; Per Sonne Holm; Hermann Lage Journal: Biochem Biophys Res Commun Date: 2007-04-02 Impact factor: 3.575
Authors: Golareh Habibi; Samuel Leung; Jennifer H Law; Karen Gelmon; Hamid Masoudi; Dmitry Turbin; Michael Pollak; Torsten O Nielsen; David Huntsman; Sandra E Dunn Journal: Breast Cancer Res Date: 2008-10-16 Impact factor: 6.466
Authors: Silvia Darb-Esfahani; Sibylle Loibl; Berit M Müller; Marc Roller; Carsten Denkert; Martina Komor; Karsten Schlüns; Jens Uwe Blohmer; Jan Budczies; Bernd Gerber; Aurelia Noske; Andreas du Bois; Wilko Weichert; Christian Jackisch; Manfred Dietel; Klaus Richter; Manfred Kaufmann; Gunter von Minckwitz Journal: Breast Cancer Res Date: 2009 Impact factor: 6.466
Authors: A R Ferreira; M Bettencourt; I Alho; A L Costa; A R Sousa; A Mansinho; C Abreu; C Pulido; D Macedo; I Vendrell; T R Pacheco; L Costa; S Casimiro Journal: J Bone Oncol Date: 2017-01-28 Impact factor: 4.072
Authors: Hongmei Zheng; Yuting Zhan; Yuting Zhang; Sile Liu; Junmi Lu; Yang Yang; Qiuyuan Wen; Songqing Fan Journal: Cancer Med Date: 2019-09-27 Impact factor: 4.452
Authors: Michaela C Huber; Natalie Falkenberg; Stefanie M Hauck; Markus Priller; Herbert Braselmann; Annette Feuchtinger; Axel Walch; Manfred Schmitt; Michaela Aubele Journal: Oncotarget Date: 2016-07-12